Celldex Therapeutics Inc (CLDX)

10.33 +0.03  +0.29% NASDAQ Aug 14, 16:59 USD

Celldex Therapeutics Income Statement (Quarterly)

Export Data

June 2020 - March 2018

Previous Periods

Income (Quarterly) 2020-06 2020-03 2019-12 2019-09 2019-06 2019-03 2018-12 2018-09 2018-06 2018-03
Operating Revenue Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Revenue 0.236M 2.728M 0.887M 0.546M 0.715M 1.425M 1.764M 0.941M 2.763M 4.068M
Cost of Goods Sold Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Gross Profit
General and Administrative Expense Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
SG&A Expense 3.528M 3.666M 3.219M 3.403M 3.908M 4.896M 4.333M 3.722M 5.621M 5.593M
Research and Development Expense 9.705M 11.70M 10.34M 11.10M 10.08M 11.15M 11.21M 11.92M 21.45M 21.88M
Income Statement Depreciation Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Amortization Expense Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Investment Write Off Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Special Income and Charges Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Operating Interest Expense Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Operating Interest Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Other Operating Expenses Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Total Operating Expenses Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Operating Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Non-Operating Interest Expense Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Non-Operating Interest Income Expense Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Other Income and Expenses Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Interest Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Pre-Tax Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Provision for Income Taxes Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Income from Continuing Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Income Attributable to Minority Interest Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Income -11.03M -12.62M -10.45M -11.41M -11.78M -17.24M -9.403M -7.243M -16.41M -118.13M
Normalized Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EBITDA Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Reconciled Depreciation Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EBIT Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Basic EPS (Quarterly) 2020-06 2020-03 2019-12 2019-09 2019-06 2019-03 2018-12 2018-09 2018-06 2018-03
EPS Basic from Continuing Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Basic from Discontinued Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Normalized Basic EPS Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Basic Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Diluted EPS (Quarterly) 2020-06 2020-03 2019-12 2019-09 2019-06 2019-03 2018-12 2018-09 2018-06 2018-03
EPS Diluted from Continuing Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Diluted from Discontinued Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Normalized Diluted EPS Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Diluted -0.50 -0.73 -0.64 -0.75 -0.84 -1.40 -0.8100 -0.66 -1.67 -12.61
Shares Data (Quarterly) 2020-06 2020-03 2019-12 2019-09 2019-06 2019-03 2018-12 2018-09 2018-06 2018-03
Average Basic Shares Outstanding Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Average Diluted Shares Outstanding Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
SEC Filing Links 2020-06 2020-03 2019-12 2019-09 2019-06 2019-03 2018-12 2018-09 2018-06 2018-03
As Originally Reported AOR AOR AOR AOR AOR AOR AOR AOR AOR AOR
Restated Restated Restated Restated Restated Restated Restated

June 2020 - March 2018

Previous Periods

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.